1. Introduction {#sec1-ijms-21-02531}
===============

In recent years, the focus of cancer therapeutics has shifted from the treatment of cancers based on type and histology to those targeting specific gene mutation and its dysregulation. Accordingly, cancer treatment regimens have advanced considerably with the development of specific inhibitors aimed at oncogenic and mutated proteins \[[@B1-ijms-21-02531]\]. [Table 1](#ijms-21-02531-t001){ref-type="table"} summarizes the tumor-driver mutations identified in melanoma, non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and thyroid cancer \[[@B2-ijms-21-02531]\].

Due to the genetic heterogeneity of cancer, standard treatments, including chemotherapy and radiation, are effective only in a subset of patients diagnosed early and with tumors that have low invasive properties. This inherent heterogeneity of cancer lends itself to the growing field of precision and personalized medicine. Personalized therapies could inhibit cancer growth and at the same time increase antitumor immunity in patients more efficiently. Targeted therapies and immunotherapies are two approaches that can generate individualized treatment. Targeted therapies target various oncogenic proteins that contribute to cancer development. Although these targeted therapies can lead to a substantial reduction of tumor size in various cancers, clinical responses tend to be temporary, and often result in tumor escape and relapse after initial treatment. [Table 2](#ijms-21-02531-t002){ref-type="table"} summarizes targeted therapies approved by the United States (US) Food and Drug Administration (FDA) for the treatment of cancer \[[@B2-ijms-21-02531]\].

Compared to targeted therapy, immunotherapy has demonstrated more enduring responses in patients with multiple types of cancer. Notably, checkpoint blockade, one form of immunotherapy, has been shown to lead to long-lasting responses; however, the response rate is lower than that of targeted therapies. Checkpoint blockade therapies target checkpoint proteins, which are involved in suppressing the immune system. [Table 3](#ijms-21-02531-t003){ref-type="table"} summarizes FDA-approved monoclonal antibodies (mAbs) and their targets for checkpoint blockade, as well as other antitumor immunotherapies \[[@B2-ijms-21-02531]\].

Despite the benefits of targeted therapies and immunotherapies, they are also associated with a number of limitations. Such limitations may be overcome by combining a targeted therapy and an immunotherapy \[[@B3-ijms-21-02531]\], and several clinical trials investigating combination therapy are ongoing to assess the safety and efficacy of these approaches. Here, we review the current status of therapies targeting the MAPK pathway and immunotherapies, mainly focusing on melanoma and NSCLC, as well as other solid cancers, such as pancreatic cancer, CRC, and thyroid cancer (clinicaltrials.gov). Major drivers of these cancers include BRAF (V600E, V599E) and/or KRAS (G12C, G12D) along the MAPK pathways while immunotherapies were considered as a monotherapy or in combination in those tumors expressing PD-1 ligands. Melanoma and NSCLC were chosen since they were shown to be refractory to conventional treatment but exhibited long-lasting responses to immunotherapies. Furthermore, colorectal cancer patients with microsatellite instability were shown to benefit from anti-PD-1 therapy while some of these patients also express BRAF V600E \[[@B4-ijms-21-02531]\]. In addition to these cancers, drivers of pancreatic cancers and thyroid cancers have been shown to exhibit KRAS (G12C, G12D) and BRAF (V599E) among MAPK pathways \[[@B5-ijms-21-02531]\]. Therefore, we expect that combination of MAPK-targeted therapies with immune checkpoint blockades could potentially compensate and synergize each other to produce long lasting antitumor effects.

2. Therapies Targeting the MAPK Pathway {#sec2-ijms-21-02531}
=======================================

Major advances have been made in the treatment of cancer through genetic and genomic tools to investigate the mechanisms of progression of several types of cancer. Targeting the MAPK pathway is a therapeutic approach aimed at oncogenic and mutated/dysregulated proteins. The main targets of these treatments have been the MEK (MAPK/ERK kinase) and BRAF proteins in the MAPK pathway. A schematic illustration of the MAPK signaling pathway and FDA-approved inhibitors of this pathway is shown in [Figure 1](#ijms-21-02531-f001){ref-type="fig"}.

In melanoma, an activating point mutation at V600 in BRAF is the main oncogenic driver \[[@B6-ijms-21-02531],[@B7-ijms-21-02531]\]. This BRAF mutation activates signaling of the MAPK pathway, and promotes cancer cell proliferation and immune escape \[[@B8-ijms-21-02531],[@B9-ijms-21-02531]\].

Subsequently, BRAF inhibitors were developed for the treatment of patients with melanoma. However, one of the early BRAF inhibitors, sorafenib, demonstrated toxicity, including non-specific side effects, and resulted in low clinical responses in patients with melanoma \[[@B10-ijms-21-02531]\]. A more effective inhibitor (vemurafenib) was later developed targeting the V600-mutated site of BRAF; this demonstrated favorable responses and resulted in an increased rate of overall survival (OS) in multiple clinical trials \[[@B11-ijms-21-02531]\]. Dabrafenib, which also targets the BRAF V600 mutation in melanoma, has demonstrated improved OS in clinical trials \[[@B12-ijms-21-02531]\]. Vemurafenib and dabrafenib were approved by the FDA as monotherapies in 2011 and 2013, respectively. Initial in vitro and in vivo studies using BRAF-targeted therapies demonstrated increased melanoma antigen expression with tumor-infiltrating CD8+ T cells, and decreased levels of VEGF and immunosuppressive cytokines. These findings demonstrate heightened CD8+ T cell targeting to tumors as well as increased levels of granzyme B and perforin---two proteases that control T cell-induced tumor apoptosis \[[@B12-ijms-21-02531]\].

For patients without the BRAF mutation, an inhibitor of MEK---a kinase downstream of RAF in the MAPK-signaling pathway---such as trametinib (FDA approved in 2013), demonstrated favorable clinical responses \[[@B13-ijms-21-02531]\]. MEK inhibitors can induce melanocyte-inducing transcription factor (MITF) and melanocyte-derived antigen expression, and enhance T cell infiltration to tumors similar to BRAF inhibitors. MEK inhibitors were also shown to generate an antitumor immune response by hindering the interaction between tumor cells and M2-like macrophages, thus allowing the tumor-specific effector T-cells to be trafficked to tumors \[[@B14-ijms-21-02531]\].

A major issue with both BRAF and MEK inhibitors is the development of gene resistance to the drugs. To reduce this resistance, combination therapy with a BRAF and a MEK inhibitor has been developed as a therapeutic approach for melanoma patients with the BRAF mutation. This combination aims to overcome resistance to a single inhibitor by focusing on vertical elements along the MAPK pathway. Combined treatment with BRAF and MEK inhibitors is currently approved, but only small advances in progression-free survival (PFS) and OS compared with BRAF inhibitor monotherapy have been reported. However, resistance continues to be an issue \[[@B15-ijms-21-02531]\].

Inhibition of the MAPK pathway in both BRAF-mutant and wild-type melanoma cells resulted in increased tumor antigen expression and T-cell function \[[@B7-ijms-21-02531]\]. Patients with melanoma treated with a BRAF inhibitor have also demonstrated enhanced antigen expression in tumors \[[@B16-ijms-21-02531]\]. The immune effects of MAPK pathway inhibitors are reported to affect T cells and dendritic cells, regardless of the BRAF mutation status \[[@B17-ijms-21-02531]\]. Patients treated with BRAF inhibitors have demonstrated preserved T cell activity and viability, highlighting their potential combination with immunotherapy \[[@B18-ijms-21-02531]\]. However, the immune response to BRAF-targeted therapies occurs early, but this response is lost upon tumor progression \[[@B19-ijms-21-02531]\]. Furthermore, PD-1 and Tim-3 expression were found to be increased in T cells and in their corresponding ligands in tumors \[[@B20-ijms-21-02531]\]. These phenotypes support the rationale for combination therapy with a MAPK-targeted inhibitor and immune checkpoint blockade (anti-PD-1, anti-PDL-1, or Tim-3).

3. Immune Checkpoint Blockade {#sec3-ijms-21-02531}
=============================

Cancer immunotherapy aims to improve the ability of the patients' immune system to destroy tumor cells. The first immunotherapy regimen developed used interleukin 2 (IL-2) to treat patients with metastatic melanoma \[[@B21-ijms-21-02531]\]. IL-2 has been reported to increase T-cell activation in a non-specific manner \[[@B9-ijms-21-02531]\]. However, due to the serious toxicity and low response rates, high doses of IL-2 are now rarely used as monotherapy \[[@B22-ijms-21-02531]\]; however, low-dose IL-2 in combination with other therapies, such as adoptive cell transfer, have demonstrated therapeutic efficacy \[[@B23-ijms-21-02531]\].

Immune checkpoints represent an area of cancer immunotherapies for which treatments are being developed. The major function of immune checkpoints is to limit immune cell activation to maintain immune homeostasis while inhibiting the development of autoimmunity. Immune checkpoint molecules are upregulated by tumor cells within the tumor microenvironment to repress the anti-cancer response of the immune system. Therefore, the use of specific mAbs to block immune checkpoints is expected to reverse the suppression of tumor-specific immune cells, including T cells and natural killer (NK) cells \[[@B24-ijms-21-02531],[@B25-ijms-21-02531]\]. Monoclonal antibodies against immune checkpoint receptors, such as CTLA-4, PD-1, and PD-L1, have demonstrated significant results in the treatment of multiple advanced cancers, including melanoma, NSCLC, head and neck, and bladder cancers \[[@B26-ijms-21-02531]\]. The interactions of PD-1, PD-L1, and CTLA-4 with their cognate ligands and clinical trials with various inhibitors are illustrated in [Figure 2](#ijms-21-02531-f002){ref-type="fig"} and [Table 4](#ijms-21-02531-t004){ref-type="table"}, respectively.

Ipilimumab, a monoclonal antibody against CTLA-4, was the first inhibitor developed for the treatment of patients with stage IV melanoma \[[@B27-ijms-21-02531]\]. CLTA-4 prevents early T-cell activation; it is not present on resting T cells but is upregulated immediately upon T cell activation \[[@B9-ijms-21-02531]\]. CTLA-4 competes with CD28 for their shared ligands, B7-1 and B7-2 (also known as CD80 and CD28, respectively), resulting in the negative regulation of T-cell signaling \[[@B28-ijms-21-02531]\]. PD-1 is another immune checkpoint molecule. Similar to CTLA-4, PD-1 is generally upregulated on activated T cells \[[@B29-ijms-21-02531]\], and negatively regulates T-cell receptor signaling and tumor killing functions by interacting with PD-L1 and PD-L2 \[[@B30-ijms-21-02531]\]. Crosslinking of PD-1 also increases the apoptosis of cytotoxic T cells \[[@B31-ijms-21-02531]\]. PD-1 blockade (for example, with nivolumab) has been investigated in multiple clinical trials in patients with melanoma, NSCLC, and CRC \[[@B32-ijms-21-02531]\]. Patients with advanced melanoma enrolled in trials investigating PD-1 therapies have demonstrated a response rate of 28%, with durable results lasting more than 1 year in 50% of responding patients \[[@B33-ijms-21-02531]\].

When used as monotherapy, currently approved checkpoint inhibitors do not lead to durable clinical responses in almost 80% of cancer patients. Patients who responded well to checkpoint therapy often had a significant number of tumor-infiltrating T cells before starting treatment. Thus, a limitation of checkpoint therapy is the lack of available activated T cells that can respond to the therapy. In addition, cancers that demonstrate an initial response may become resistant to checkpoint therapy, which would further reduce treatment efficacy \[[@B34-ijms-21-02531]\].

Among anti-CTLA-4 and PD-1 treatments, the latter have been shown to be more effective. A study comparing ipilimumab with pembrolizumab (another PD-1 antibody) reported 6-month PFS of 26.5% and 47.3%, respectively. Anti-PD-1 therapies have also been shown to result in fewer adverse events compared with anti-CTLA-4 therapies. This is likely due to the expression of PD-1 on mature T cells (such as dendritic cells and macrophages), while CLTA-4 is present on T cells throughout the body, including those in the lymph nodes and skin \[[@B35-ijms-21-02531]\].

Combination therapy using PD-1 and CLTA-4 antibodies has been studied to enhance efficacy and reduce toxicity. Since CTLA-4 and PD-1 therapies function through different mechanisms, their use in combination can generate a synergistic effect, thus limiting the side effects from a single checkpoint inhibitor. Checkpoint monotherapy also has been shown to activate alternative T-cell checkpoints; thus, therapy targeting one checkpoint will result in the upregulation of another checkpoint, which may exacerbate tumor effects \[[@B35-ijms-21-02531]\]. Recent clinical trials showed that blocking CTLA-4 and PD-1 simultaneously in patients with advanced melanoma strengthened the function of tumor-specific T cells, but resulted in off-target/on-target side effects \[[@B36-ijms-21-02531]\]. Consequently, alternative combinations with other checkpoint inhibitors or targeted therapies are being developed in an attempt to reduce toxicities.

4. Combination of Immunotherapy and Targeted Therapy {#sec4-ijms-21-02531}
====================================================

Melanomas, like many types of cancer, are capable of evading cell death by suppressing the immune system. One of these mechanisms involves the activation of PD-L1 expression by the release of cytokines (such as interferon-gamma) in tumor-infiltrating lymphocytes (TILs). Immune resistance has been demonstrated in BRAF inhibitor-resistant melanoma cell lines with increased PD-L1 expression, which permitted host immune cell evasion \[[@B15-ijms-21-02531]\]. Despite the development of resistance, in the early stages of treatment, BRAF (and MAPK) inhibitors can stimulate the immune response against tumors.

BRAF and MEK inhibitors can also enhance intratumoral T cell infiltration. Many studies have shown increased T cells in BRAF-mutated melanomas following treatment with MAPK pathway inhibitors; however, this increase is lost as therapy progresses. MAPK pathway inhibitors can also protect CD8 effector T cells from death through chronic T-cell receptor stimulation. As noted above, MEK inhibitors exert their immune-stimulatory effects by increasing melanocyte-derived antigen expression, increasing T cell infiltration, and reducing the interaction between tumor cells and M2-like macrophages. This increase in tumor antigen levels may augment antitumor T-cell responses \[[@B15-ijms-21-02531]\]. However, MEK inhibitors may have adverse effects on naive T cell proliferation, viability, and interferon gamma secretion.

While MAPK inhibitors can induce temporary responses, many of these are not durable. Melanoma patients carrying a BRAF mutation have been shown to exhibit some short-term benefits from targeted therapies, such as MAPK inhibitors. Conversely, immunotherapy (such as immune checkpoint blockades) has been shown to induce longer-term responses in approximately one-third of patients \[[@B14-ijms-21-02531]\]. Recent studies suggested that short-term inhibition of both BRAF and MEK in combination with anti-PD-1/L1 antibodies could enhance tumor immune infiltration, and improve tumor control in a CD8 T cells-dependent manner. Combination therapy with MAPK inhibitors and immune checkpoint inhibitors may overcome some of the limitations associated with the monotherapies.

Clinical trials are currently ongoing to investigate combinations of immune checkpoint blockades (particularly anti-PD-1/L1 therapies) with BRAF and/or MEK inhibitors. A long-term study is needed to determine the potential toxicity of each single agent when used in combination therapy. One phase I study reported preliminary clinical activity and a tolerable safety profile for an anti-PD-L1 antibody in combination with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in BRAF-mutated melanoma as well as in BRAF wild-type melanoma \[[@B37-ijms-21-02531]\]. An ongoing phase II study is currently investigating the efficacy of pembrolizumab (anti-PD-1 therapy) in combination with intermittent or continuous administration of BRAF and MEK inhibitors (dabrafenib and trametinib) in patients with advanced melanoma (NCT02625337) \[[@B38-ijms-21-02531],[@B39-ijms-21-02531]\].

Optimizing the sequence in which checkpoint inhibitors and targeted therapies are given (sequential rather than in combination) may also have potential benefits, such as reduced toxicity and reduced costs associated with concurrent approaches used over long periods. In a phase II trial (CA184-240/NCT01673854), ipilimumab was introduced after 6 weeks of vemurafenib therapy, preventing the liver toxicity observed when the treatments were used simultaneously \[[@B38-ijms-21-02531]\]. In that trial, sequential treatment was tolerable, and resulted in a median PFS of 4.4 months and an overall response rate (ORR) of 30% following initial vemurafenib and ipilimumab treatment \[[@B38-ijms-21-02531]\]. Regardless of whether BRAF and/or MAPK inhibitors are administered sequentially or in combination with an immune checkpoint inhibitor, treatment with both agents leads to more durable responses in patients with BRAF-mutated melanoma \[[@B38-ijms-21-02531]\]. This is likely due to the compensatory and synergistic relationship between the two types of therapies. Approaches to integrate targeted therapies with immunotherapies have helped to overcome the limitations of each individual regimen and strengthen the responses to monotherapy. Here, we review ongoing clinical trials in patients with melanoma, NSCLC, colon cancer, pancreatic cancer, and thyroid cancer. We also added adverse effects of the combination therapies of melanoma. Since clinical trials of other types of cancer have not been completed or terminated, their adverse side effects have not been available yet.

4.1. Melanoma {#sec4dot1-ijms-21-02531}
-------------

The primary treatment option for patients with early-stage melanoma is surgery; however, surgery is not the best solution for patients with advanced melanoma due to the high rate of metastasis. Generally, conventional chemotherapy is used for patients with late-stage melanoma, but the response rate is very poor, at approximately 5% \[[@B40-ijms-21-02531],[@B41-ijms-21-02531]\]. However, following the recent development of targeted therapies and immunotherapies, substantial improvements have been made in the prognosis of melanoma. The BRAF V600 mutation leads to the constitutive activation of the MAPK pathway in more than 50% of patients with melanoma \[[@B42-ijms-21-02531]\]. Following approval of the BRAF inhibitor vemurafenib by the FDA in 2011 for patients with advanced melanoma, PFS and OS rates have improved significantly \[[@B11-ijms-21-02531]\]. In 2013, another BRAF inhibitor, dabrafenib, was approved by the FDA, and was shown to improve function compared with vemurafenib \[[@B43-ijms-21-02531]\]. These inhibitors were found to result in remarkable clinical responses in the short term; however, long-term responses are uncommon due to acquired resistance \[[@B44-ijms-21-02531]\].

Since MAPK pathways are reactivated by the BRAF mutation, MEK (MAPK Kinase) inhibitors, including trametinib, have been developed. Trametinib inhibits MEK1/2 and was the first MEK inhibitor to be approved by the FDA for the treatment of patients with advanced melanoma \[[@B45-ijms-21-02531]\]. The combination of encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor) was recently approved by the FDA for the treatment of patients with advanced melanoma. Patients with BRAF-mutated melanoma have shown improved PFS and OS following combination treatment with these MAPK pathway inhibitors \[[@B46-ijms-21-02531]\]; however, decreased clinical responses have been reported in patients following several months of treatment \[[@B47-ijms-21-02531]\]. Ongoing clinical trials investigating the treatment of melanoma are shown in [Table 5](#ijms-21-02531-t005){ref-type="table"} \[[@B38-ijms-21-02531]\].

To enhance the clinical response to therapies targeting the MAPK pathway, clinical trials are investigating regimens that incorporate both targeted therapies and immunotherapies, specifically immune checkpoint inhibitors. For example, NCT01400451 is investigating the efficacy and safety of vemurafenib (BRAF inhibitor) in combination with ipilimumab (CTLA-4-Ab) for the treatment of patients with metastatic melanoma expressing an activated mutant form of BRAF V600E \[[@B38-ijms-21-02531]\]. NCT01400451 was closed to enrollment and Phase II was not initiated, because the drug combination was not fully tolerated, and the highest tolerable dosage was not established \[[@B38-ijms-21-02531]\]. The adverse event was unexpected grade 2/3 hepatotoxicity \[[@B38-ijms-21-02531]\]. NCT01673854 is investigating the safety of vemurafenib, administered at 960 mg for 6 weeks along with ipilimumab in a sequential manner, to BRAF V600-mutated melanoma patients \[[@B38-ijms-21-02531]\]. No severe hepatotoxicity was observed, but a grade 3/4 skin adverse event has been reported \[[@B38-ijms-21-02531]\]. NCT03554083 is studying the effect of combined treatment with cobimetinib (MEK inhibitor) and atezolizumab (PD-L1-Ab), and with vemurafenib (BRAF inhibitor), cobimetinib, and atezolizumab for the treatment of patients with high-risk stage III melanoma \[[@B38-ijms-21-02531]\]. NCT03235245 is a phase II study evaluating the effect of combination targeted therapy (encorafenib and binimetinib) followed by combination immunotherapy (ipilimumab and nivolumab) compared with combination immunotherapy alone (ipilimumab and nivolumab) in patients with BRAF V600-mutated unresectable or metastatic melanoma \[[@B38-ijms-21-02531]\]. NCT02967692 is a phase III study evaluating the safety and efficacy of the combination spartalizumab (anti-PD-1 antibody), dabrafenib (BRAF inhibitor), and trametinib (MEK inhibitor) in patients with unresectable or metastatic BRAF V600-mutated melanoma \[[@B38-ijms-21-02531]\]. Adverse events of any grade included pyrexia (*n* = 14, 61%), arthralgia, fatigue, rash, and vomiting (*n* = 4 each, 17%) \[[@B38-ijms-21-02531]\]. NCT02902042 is a phase I/II study investigating the efficacy and safety of encorafenib (BRAF inhibitor) combined with binimetinib (MEK inhibitor) and pembrolizumab (anti-PD-1 antibody) in patients with BRAF V600-mutated unresectable or metastatic melanoma \[[@B38-ijms-21-02531]\]. NCT02858921 is a phase II trial designed to determine the optimal combination of drugs (dabrafenib, trametinib, and/or pembrolizumab) to reduce tumor size prior to surgery for patients with BRAF V600-mutated, resectable stage IIIB/C melanoma \[[@B38-ijms-21-02531]\]. That study is also examining drug combinations to prevent the recurrence of melanoma after resection.

4.2. Non-Small-Cell Lung Cancer (NSCLC) {#sec4dot2-ijms-21-02531}
---------------------------------------

Lung cancer occurs at a high incidence and is associated with mortality in both males and females. Patients with early-stage (stage I, II, and IIIA) resectable NSCLC generally undergo surgery to remove the tumor \[[@B48-ijms-21-02531]\]. However, about 80% of lung cancers are diagnosed as advanced-stage NSCLC, for which surgical resection is not a suitable strategy. In addition, tumor recurrence can occur within a few years of surgery \[[@B49-ijms-21-02531]\]. Therefore, chemotherapy is used the first-line treatment for patients with late-stage NSCLC patients \[[@B48-ijms-21-02531]\].

Increased knowledge on the correlation between the immune system and lung cancer has led to the development of immunotherapies for the treatment of patients with NSCLC. The success of anti-PD-1/PD-L1 antibodies has been reported in multiple clinical trials, with significant responses and low toxicities observed in patients with NSCLC \[[@B50-ijms-21-02531]\]. Chemotherapy has been shown to have minimal effects in patients with high PD-L1 levels and low expression of causative mutations. Chemotherapy was found to enhance the amount of PD-L1 on tumor cells, as well as the number of TILs \[[@B51-ijms-21-02531]\]; hence, immune checkpoint inhibitors combined with chemotherapy have shown promising clinical results \[[@B52-ijms-21-02531],[@B53-ijms-21-02531]\].

Over the past decades, there has been substantial progress in the treatment of patients with NSCLC due to the development of therapies targeting mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) translocations \[[@B54-ijms-21-02531]\]. Most EGFR mutations comprise exon 19 deletions and exon 21 L858R mutations; these lead to the constitutive activation of downstream signaling events, including MAPK, phosphoinositide 3-kinase (PI3K), and signal transducer and activator of transcription (STAT) \[[@B55-ijms-21-02531]\].

Ongoing clinical trials in NSCLC combining MAPK inhibitors and immune checkpoint inhibitors are reviewed in [Table 6](#ijms-21-02531-t006){ref-type="table"} \[[@B38-ijms-21-02531]\]. NCT03991819 is a phase I/Ib study investigating the efficacy, safety, and best dose of binimetinib (MEK inhibitor) in combination with pembrolizumab (anti-PD-1 antibody) for the treatment of patients with advanced NSCLC \[[@B38-ijms-21-02531]\]. The phase I part of study NCT03991819 comprises a dose de-escalation to determine the maximum dose of binimetinib that can be administered with pembrolizumab without having significant adverse events \[[@B38-ijms-21-02531]\]. The efficacy, safety, tolerability, and antitumor activity of the dose determined in the phase I part will be evaluated in the phase Ib part \[[@B38-ijms-21-02531]\]. NCT03600701 is a phase II trial assessing the effect of atezolizumab (anti-PD-L1 antibody) and cobimetinib (MEK inhibitor) for the treatment of patients with metastatic, recurrent, or refractory NSCLC \[[@B38-ijms-21-02531]\]. NCT03581487 is a phase I/II trial analyzing the best dose of selumetinib (MEK inhibitor) in combination with durvalumab (anti-PD-L1 antibody) and tremelimumab (CTLA-4-Ab) for the treatment of patients with stage IV or recurrent NSCLC \[[@B38-ijms-21-02531]\]. NCT03299088 is a phase Ib study investigating the safety of pembrolizumab (anti-PD-1 antibody) and trametinib (MEK inhibitor) for the treatment of patients with metastatic KRAS-mutated NSCLC \[[@B38-ijms-21-02531]\]. NCT03225664 is a phase Ib/II trial assessing the safety and best dose of trametinib (MEK inhibitor) in combination with pembrolizumab (anti-PD-1 antibody) for the treatment of patients with metastatic, recurrent, locally advanced, and unresectable NSCLC \[[@B38-ijms-21-02531]\].

4.3. Colorectal Cancer (CRC) {#sec4dot3-ijms-21-02531}
----------------------------

CRC is the third most common cancer worldwide \[[@B56-ijms-21-02531]\], and OS for patients with metastatic CRC remains low. Standard treatment of CRC includes surgery followed by adjuvant chemotherapy \[[@B57-ijms-21-02531],[@B58-ijms-21-02531]\]. Common mutations of CRC, including KRAS, p53, SMAD4, and BRAF play significant roles in CRC metastasis \[[@B57-ijms-21-02531]\]. Clinical trials investigating MAPK inhibitors in patients with CRC are summarized in [Table 7](#ijms-21-02531-t007){ref-type="table"} \[[@B38-ijms-21-02531]\]. In trial NCT01436656, a 300 mg dosage of encorafenib once daily was declared the recommended phase II dose (RP2D) \[[@B59-ijms-21-02531]\]. The most common adverse events were nausea, myalgia, and palmar--plantar erythrodysesthesia \[[@B59-ijms-21-02531]\]. In BRAF inhibitor-naive patients, the ORR and median PFS (mPFS) were 60% and 12.4 months, respectively \[[@B59-ijms-21-02531]\]. In BRAF inhibitor-pretreated patients, the ORR and mPFS were 22% and 1.9 months, respectively \[[@B59-ijms-21-02531]\]. In trial NCT00959127, the maximum tolerated dose (MTD) was 60 mg twice daily with a subsequent decrease to 45 mg twice daily due to the frequency of treatment-related ocular toxicities \[[@B60-ijms-21-02531]\]. Common adverse events were mostly grade 1/2 rash, nausea, vomiting, diarrhea, peripheral edema, and fatigue \[[@B60-ijms-21-02531]\]. Target inhibition was observed in serum and skin biopsy samples \[[@B60-ijms-21-02531]\].

Although immune checkpoint inhibitors, including anti-PD-1 antibodies (nivolumab, pembrolizumab), anti-PD-L1 antibodies (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 antibodies (ipilimumab, tremelimumab), have demonstrated efficacy in many cancers, no favorable clinical responses have been reported in patients with CRC \[[@B58-ijms-21-02531]\]. However, immune checkpoint inhibitors may have a more favorable effect when used in combination with MAPK pathway-targeted therapy. Due to the low efficacy observed with immune checkpoint inhibitors in patients with CRC, combination strategies including targeted therapies and chemotherapy have been developed to enhance the immune response of these patients. Ongoing clinical trials investigating the combination treatment of CRC with an immune checkpoint inhibitor and MAPK-targeted therapy are presented in [Table 8](#ijms-21-02531-t008){ref-type="table"} \[[@B38-ijms-21-02531]\]. NCT04044430 is a phase I/II trial investigating the effects of encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and nivolumab (anti-PD-1 antibody) in patients with microsatellite stable (MSS), BRAF V600E-mutated metastatic CRC \[[@B38-ijms-21-02531]\]. Trial NCT03428126 is investigating the efficacy and safety of durvalumab (anti-PD-L1 antibody) and trametinib (MEK inhibitor) in patients with MSS CRC. Durvalumab is an FDA-approved antibody used for the treatment of patients with previously treated advanced bladder cancer. Trametinib is an FDA-approved MEK inhibitor targeting advanced melanoma bearing BRAF V600E or V600K mutation with dabrafenib (BRAF inhibitor) \[[@B38-ijms-21-02531]\]. NCT03374254 is a phase Ib study examining the efficacy and safety of combined pembrolizumab (anti-PD-1 antibody) and binimetinib (MEK inhibitor), compared with combined pembrolizumab and chemotherapy, with or without binimetinib, in patients with metastatic CRC \[[@B38-ijms-21-02531]\]. NCT03374254 is a multi-cohort study aiming to establish the recommended phase 2 dose (RP2D) of the following five combinations (cohorts): cohort A, pembrolizumab and binimetinib; cohort B, pembrolizumab and mFOLFOX7 (oxaliplatin 85 mg/m^2^, leucovorin (calcium folinate) 400 mg/m^2^, fluorouracil (5-FU) 2400 mg/m^2^); cohort C, pembrolizumab with mFOLFOX7 and binimetinib; cohort D, pembrolizumab, FOLFIRI (irinotecan 180 mg/m^2^, leucovorin (calcium folinate) 400 mg/m^2^, 5-FU 2400 mg/m^2^ over 46--48 h); and cohort E, pembrolizumab plus FOLFIRI and binimetinib \[[@B38-ijms-21-02531]\].

4.4. Pancreatic Cancer {#sec4dot4-ijms-21-02531}
----------------------

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and the mortality rate is almost equivalent to the occurrence rate \[[@B61-ijms-21-02531]\]. At the time of diagnosis, it is usually too late for surgical resection, since most patients already have advanced and metastatic disease. The 5-year survival rate for patients with PDAC is less than 10%, primarily due to the delayed diagnosis \[[@B61-ijms-21-02531]\]. The driver mutations of PDAC include high rate of activated *KRAS* mutations, and inactivated form of mutations of *TP53, SMAD4/DPC4*, and *P16/CDKN2A* \[[@B62-ijms-21-02531]\]. Other characteristics of PDAC include a lack of specific markers, a low response to chemotherapy, and a very low response rate to targeted therapies against MEK, PI3K, and EGFR \[[@B63-ijms-21-02531],[@B64-ijms-21-02531],[@B65-ijms-21-02531]\]. This is related to the innate or acquired resistance of pancreatic cancer cells to these therapies \[[@B66-ijms-21-02531],[@B67-ijms-21-02531]\].

The tumor microenvironment (TME) of PDAC includes a highly complex structure, in which a large proportion of cancer cells and the extracellular matrix is resistant to permeation by chemotherapeutic drugs \[[@B68-ijms-21-02531]\]. The lack of successful clinical results in patients with PDAC is possibly due to immune suppression and escape \[[@B69-ijms-21-02531]\]. While immune checkpoint inhibitors have demonstrated significant clinical benefits in various types of cancers, including melanoma, lung, renal, and hematological cancers \[[@B70-ijms-21-02531],[@B71-ijms-21-02531],[@B72-ijms-21-02531],[@B73-ijms-21-02531],[@B74-ijms-21-02531]\], their efficacy in patients with PDAC is poor, with no clinical benefits observed \[[@B75-ijms-21-02531]\].

Despite this resistance of PDAC to several therapeutic strategies, a phase Ib/II clinical trial (NCT03193190) investigating combination therapy with cobimetinib (MEK inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with metastatic PDAC is now underway; however, the results are still pending ([Table 9](#ijms-21-02531-t009){ref-type="table"}) \[[@B38-ijms-21-02531]\]. This study includes two patient cohorts: cohort 1, patients without any prior systemic therapy; and cohort 2, patients with one line of prior systemic therapy \[[@B38-ijms-21-02531]\]. Another clinical trial (NCT03637491) investigating avelumab (anti-PD-L1 antibody) combined with binimetinib (MEK inhibitor) in patients with PDAC is also underway ([Table 9](#ijms-21-02531-t009){ref-type="table"}) \[[@B38-ijms-21-02531]\]. NCT03637491 is a phase 1b/2 study testing the effects of avelumab (anti-PD-L1 antibody), binimetinib (MEK inhibitor), and talazoparib (poly ADP ribose polymerase (PARP) inhibitor) in combination as two or three drugs for patients with metastatic PDAC and locally advanced or metastatic KRAS- or NRAS-mutated solid tumors \[[@B38-ijms-21-02531]\]. The phase Ib part will evaluate the optimal combination of drugs, and their doses, and phase II will study the safety and efficacy of these drugs in terms of side effects and tumor growth \[[@B38-ijms-21-02531]\].

4.5. Thyroid Cancer {#sec4dot5-ijms-21-02531}
-------------------

Thyroid cancer is the most common endocrine tumors \[[@B76-ijms-21-02531]\]. Standard therapy for patients with thyroid cancer includes surgery and treatment with radioactive iodine \[[@B77-ijms-21-02531],[@B78-ijms-21-02531]\]. The major driver mutations of thyroid cancer include *BRAF* and *RAS* mutations, and transfusion/papillary thyroid carcinoma (*RET/PTC)* rearrangements \[[@B79-ijms-21-02531]\].

Although use of a targeted therapy against the MAPK pathway generated a favorable clinical response in patients with thyroid cancer, the OS rate remains controversial \[[@B80-ijms-21-02531]\]. This may be due to the toxicity of the MAPK inhibitor and the resistance of the tumor microenvironment. Therefore, new strategies are required to overcome these limitations.

Reports have shown that combination therapy with a MAPK pathway-targeted inhibitor and immunotherapy may induce favorable responses in patients with thyroid cancer based on the immunomodulatory effect of MAPK inhibitors. NCT04061980 is a phase II clinical trial combining a MAPK inhibitor and a PD-1 inhibitor \[[@B38-ijms-21-02531]\]; this study aims to assess the efficacy and safety of encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor) with or without nivolumab (anti-PD-1 antibody) in patients with BRAF V600-mutated metastatic and refractory thyroid cancer not responsive to radioiodine treatment ([Table 10](#ijms-21-02531-t010){ref-type="table"}) \[[@B38-ijms-21-02531]\]. Encorafenib and binimetinib have been reported to inhibit the tumor growth, and nivolumab is an anti-PD1 monoclonal antibody that boosts the immune system to suppress tumor metastasis and growth \[[@B38-ijms-21-02531]\]. Clinical trials investigating treatments for various forms of cancer have demonstrated the feasibility of combination therapy using MAPK inhibitors and checkpoint blockers, and the ability of this approach to overcome the limitations associated with the respective monotherapy.

5. Conclusions {#sec5-ijms-21-02531}
==============

Despite the clinical success of cancer immunotherapies, many hurdles and challenges remain. Although targeted therapy is a promising therapeutic option for various types of cancer, the development of acquired resistance remains a significant limitation. Conversely, immunotherapy has been shown to generate long-term effects, but has a low response rate. Increasingly, reports have shown that the effects of targeted therapies are enhanced when used in combination with immune cells and their microenvironments.

Combination therapies target signal transduction cascades required for tumor cell survival and maintenance. While small-molecule inhibitors block intracellular targets, checkpoint inhibitors restore a patient's immune system, enabling the killing of tumor cells as well as metastatic cells and those with acquired mutations. Therefore, it is important to understand the patient's individual tumor mutation burden to select the optimal personalized combination regimen. When discerning a patient's mutation burden, combined treatment with an immune checkpoint inhibitor and a MAPK inhibitor is an effective strategy to overcome resistance to targeted therapies. Further in-depth analyses of the mechanisms of acquired resistance are required to enable the identification of alternatives that restore tumor-specific T cells and reprogram an immunosuppressive tumor microenvironment.
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###### 

Genetic drivers of cancer.

  Type of Cancer               Mutations
  ---------------------------- --------------------------------------------------------------------
  Melanoma                     *IDH1, RB1, DDX3X, NF1, BRAF, RAS,*
  Non-small-cell lung cancer   *PI3K, FGFR, DDR2, PTEN, KRAS, EGFR, BRAF, ALK*
  Colorectal cancer            *APC, KRAS, TP53, SMAD4, FBXW7, BRAF, PI3K*
  Pancreatic cancer            *KRAS,BRAF,TP53, CDKN2A*, *SMAD4*, *MLL3, TGFBR2, ARID1A*, *SF3B1*
  Thyroid cancer               *RAS, BRAF, TP53, PI3K, RET/PTC*
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###### 

Food and Drug Administration (FDA)-approved targeted therapies for cancer.

  Name of Drug                                              Company                                            Target                                          Conditions
  --------------------------------------------------------- -------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Everolimus (Afinitor)                                     Novartis                                           mTOR                                            Pancreatic, gastrointestinal, or lung origin neuroendocrine tumorsRenal cell carcinomaNonresectable subependymal giant cell astrocytoma associated with tuberous sclerosisBreast cancer (HR+, HER2−)
  Tamoxifen (Nolvadex)                                      AstraZeneca                                        Estrogen receptor (ER)-positive breast cancer   Breast cancerDuctal carcinoma in situ
  Lapatinib (Tykerb)                                        GlaxoSmithKline                                    HER2 (ERBB2/neu), EGFR (HER1/ERBB1)             Breast cancer (HER2+)
  Neratinib (Nerlynx)                                       Puma Biotech                                       HER2 (ERBB2/neu)                                Breast cancer (HER2 overexpressed/amplified)
  Palbociclib (Ibrance)                                     Pfizer                                             CDK4, CDK6                                      Breast cancer (HR+, HER2−)
  Ribociclib (Kisqali)                                      Novartis                                           CDK4, CDK6                                      Breast cancer (HR+, HER2−)
  Ado-trastuzumab emtansine (Kadcyla)                       Genentech                                          HER2 (ERBB2/neu)                                Breast cancer (HER2+)
  Trastuzumab (Herceptin)                                   Genentech                                          HER2 (ERBB2/neu)                                Breast cancer (HER2+)Gastric cancer (HER2+)
  Erdafitinib (Balversa™)                                   Astex Pharmaceuticals and Janssen Pharmaceutical   FGFR                                            Urothelial carcinoma
  Axitinib (Inlyta)                                         Chiron                                             KIT, PDGFRβ, VEGFR1/2/3                         Renal cell carcinoma
  Lenvatinib (Lenvima)                                      Eisai                                              VEGFR2                                          Renal cell carcinomaThyroid cancer
  Sorafenib (Nexavar)                                       Bayer                                              VEGFR, PDGFR, KIT, RAF                          Hepatocellular carcinomaRenal cell carcinomaThyroid carcinoma
  Temsirolimus (Torisel)                                    Pfizer                                             mTOR                                            Renal cell carcinoma
  Pazopanib (Votrient)                                      GlaxoSmithKline                                    VEGFR, PDGFR, KIT                               Renal cell carcinoma
  Cabozantinib (Cabometyx (tablet), Cometriq (capsule\]))   Exelixis                                           FLT3, KIT, MET, RET, VEGFR2                     Medullary thyroid cancerRenal cell carcinoma
  Afatinib (Gilotrif)                                       Boehringer Ingelheim                               EGFR (HER1/ERBB1), HER2 (ERBB2/neu)             Non-small-cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)
  Alectinib (Alecensa)                                      Genentech                                          ALK                                             Non-small-cell lung cancer (with ALK fusion)
  Brigatinib (Alunbrig)                                     Takeda Pharmaceutical                              ALK                                             Non-small-cell lung cancer (ALK+)
  Ceritinib (Zykadia)                                       Novartis                                           ALK                                             Non-small-cell lung cancer (with ALK fusion)
  Crizotinib (Xalkori)                                      Pfizer                                             ALK, MET, ROS1                                  Non-small-cell lung cancer (with ALK fusion or ROS1 gene alteration)
  Erlotinib (Tarceva)                                       Roche                                              EGFR (HER1/ERBB1)                               Non-small-cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)Pancreatic cancer
  Gefitinib (Iressa)                                        AstraZeneca                                        EGFR (HER1/ERBB1)                               Non-small-cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)
  Osimertinib (Tagrisso)                                    AstraZeneca                                        EGFR                                            Non-small-cell lung cancer (with EGFR T790M mutation)
  Cobimetinib (Cotellic)                                    Genentech                                          MEK                                             Melanoma (with BRAF V600E or V600K mutation)
  Dabrafenib (Tafinlar)                                     GlaxoSmithKline                                    BRAF                                            Melanoma (with BRAF V600 mutation)Non-small-cell lung cancer (with BRAF V600E mutation)
  Necitumumab (Portrazza)                                   Eli Lilly                                          EGFR (HER1/ERBB1)                               Squamous non-small-cell lung cancer
  Bortezomib (Velcade)                                      Takeda                                             Proteasome                                      Multiple myelomaMantle cell lymphoma
  Bosutinib (Bosulif)                                       Pfizer                                             ABL                                             Chronic myelogenous leukemia (Philadelphia chromosome positive)
  Carfilzomib (Kyprolis)                                    Onyx                                               Proteasome                                      Multiple myeloma
  Dasatinib (Sprycel)                                       Bristol-Myers Squibb                               ABL                                             Chronic myelogenous leukemia (Philadelphia chromosome positive)Acute lymphoblastic leukemia (Philadelphia chromosome positive)
  Enasidenib (Idhifa)                                       Agios Pharmaceuticals/Celgene                      IDH2                                            Acute myeloid leukemia (with IDH2 mutation)
  Venetoclax (Venclexta)                                    AbbVie and Roche                                   BCL2                                            Chronic lymphocytic leukemia (with 17p deletion)
  Ibrutinib (Imbruvica)                                     Johnson &Johnson                                   BTK                                             Mantle cell lymphomaChronic lymphocytic leukemiaWaldenstrom's macroglobulinemia
  Idelalisib (Zydelig)                                      Gilead                                             PI3Kδ                                           Chronic lymphocytic leukemiaFollicular B-cell non-Hodgkin's lymphomaSmall lymphocytic lymphoma
  Ixazomib (Ninlaro)                                        Takeda Pharmaceutical                              Proteasome                                      Multiple myeloma
  Midostaurin (Rydapt)                                      Novartis                                           FLT3                                            Acute myeloid leukemia (FLT3+)
  Nilotinib (Tasigna)                                       Novartis                                           ABL                                             Chronic myelogenous leukemia (Philadelphia chromosome positive)
  Ponatinib (Iclusig)                                       ARIAD                                              ABL, FGFR1--3, FLT3, VEGFR2                     Chronic myelogenous leukemiaAcute lymphoblastic leukemia (Philadelphia chromosome positive)
  Trametinib (Mekinist)                                     GlaxoSmithKline                                    MEK                                             Melanoma (with BRAF V600 mutation)Non-small-cell lung cancer (with BRAF V600E mutation)
  Vemurafenib (Zelboraf)                                    Genentech                                          BRAF                                            Melanoma (with BRAF V600 mutation)
  Cetuximab (Erbitux)                                       Eli Lilly                                          EGFR (HER1/ERBB1)                               Colorectal cancer (KRAS wild type)Squamous cell cancer of the head and neck
  Ziv-aflibercept (Zaltrap)                                 Sanofi-Aventis                                     PIGF, VEGFA/B                                   Colorectal cancer
  Panitumumab (Vectibix)                                    Amgen                                              EGFR (HER1/ERBB1)                               Colorectal cancer (KRAS wild type)
  Ramucirumab (Cyramza)                                     Eli Lilly                                          VEGFR2                                          Colorectal cancerGastric cancer or gastroesophageal junction (GEJ) adenocarcinomaNon-small-cell lung cancer
  Regorafenib (Stivarga)                                    Bayer                                              KIT, PDGFRβ, RAF, RET, VEGFR1--3                Colorectal cancerGastrointestinal stromal tumorsHepatocellular carcinoma
  Rucaparib (Rubraca)                                       Clovis Oncology                                    PARP                                            Ovarian cancer (with BRCA mutation)
  Niraparib (Zejula)                                        Tesaro                                             PARP                                            Ovarian cancerFallopian tube cancerPeritoneal cancer
  Olaparib (Lynparza)                                       AstraZeneca                                        PARP                                            Ovarian cancer (with BRCA mutation)
  Denosumab (Xgeva)                                         Amgen                                              RANKL                                           Giant cell tumor of the bone
  Dinutuximab (Unituxin)                                    United Therapeutics                                B4GALNT1 (GD2)                                  Pediatric neuroblastoma
  Imatinib (Gleevec)                                        Novartis                                           KIT, PDGFR, ABL                                 GI stromal tumor (KIT+)Dermatofibrosarcoma protuberansMultiple hematological malignancies including Philadelphia chromosome-positive ALL and CML
  Sonidegib (Odomzo)                                        Novartis                                           Smoothened                                      Basal cell carcinoma
  Vismodegib (Erivedge)                                     Roche                                              PTCH, Smoothened                                Basal cell carcinoma
  Olaratumab (Lartruvo)                                     Eli Lilly                                          PDGFRα                                          Soft tissue sarcoma
  Ruxolitinib (Jakafi)                                      Incyte                                             JAK1/2                                          Myelofibrosis
  Tofacitinib (Xeljanz)                                     Pfizer                                             JAK3                                            Rheumatoid arthritis
  Vandetanib (Caprelsa)                                     AstraZeneca                                        EGFR (HER1/ERBB1), RET, VEGFR2                  Medullary thyroid cancer
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###### 

FDA-approved drugs for immunotherapy.

  Name of Drug                                     Company                  Target                     Conditions
  ------------------------------------------------ ------------------------ -------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alemtuzumab (Campath)                            Sanofi                   CD52                       B-cell chronic lymphocytic leukemia
  Atezolizumab (Tecentriq)                         Genentech                PD-L1                      Urothelial carcinomaNon-small-cell lung cancer
  Avelumab (Bavencio)                              Merck KGaA and Pfizer    PD-L1                      Merkel cell carcinomaUrothelial cancer
  Blinatumomab (Blincyto)                          Amgen                    CD19/CD3                   Acute lymphoblastic leukemia (precursor B-cell)
  Brentuximab vedotin (Adcetris)                   Takeda Pharmaceutical    CD30                       Hodgkin lymphomaAnaplastic large cell lymphoma
  Canakinumab (Ilaris)                             Novartis                 IL-1β                      Juvenile idiopathic arthritisCryopyrin-associated periodic syndromes
  Daratumumab (Darzalex)                           Janssen Pharmaceutical   CD38                       Multiple myeloma
  Durvalumab (Imfinzi)                             MedImmune/AstraZeneca    PD-L1                      Urothelial carcinomaNon-small-cell lung cancer
  Elotuzumab (Empliciti)                           Bristol-Myers Squibb     SLAMF7 (CS1/CD319/CRACC)   Multiple myeloma
  Ibritumomab tiuxetan (Zevalin)                   Biogen IDEC              CD20                       Non-Hodgkin's lymphoma
  Ipilimumab (Yervoy)                              Bristol-Myers Squibb     CTLA-4                     MelanomaRenal cell carcinoma
  Nivolumab (Opdivo)                               Bristol-Myers Squibb     PD-1                       Colorectal cancer (dMMR and MSI-H)Head and neck squamous cell carcinomaHepatocellular carcinomaHodgkin lymphomaMelanomaNon-small-cell lung cancerRenal cell carcinomaUrothelial carcinoma
  Obinutuzumab (Gazyva)                            Roche                    CD20                       Chronic lymphocytic leukemiaFollicular lymphoma
  Ofatumumab (Arzerra, HuMax-CD20)                 Roche                    CD20                       Chronic lymphocytic leukemia
  Pembrolizumab (Keytruda)                         Merck &Co                PD-1                       Classical Hodgkin lymphomaColorectal cancer (MSI-H/dMMR)Gastric cancerMelanomaNon-small-cell lung cancer (PD-L1+)Head and neck squamous cell carcinomaUrothelial cancerSolid tumors (MSI-H/dMMR)
  Rituximab (Rituxan, Mabthera)                    Roche                    CD20                       Non-Hodgkin's lymphomaChronic lymphocytic leukemiaRheumatoid arthritisGranulomatosis with polyangiitis
  Rituximab/hyaluronidase human (Rituxan Hycela)   Roche                    CD20                       Chronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphoma
  Siltuximab (Sylvant)                             Janssen Pharmaceutical   IL-6                       Multicentric Castleman's disease
  Tocilizumab (Actemra)                            Genentech                IL-6R                      Rheumatoid arthritisJuvenile idiopathic arthritis
  Tositumomab (Bexxar)                             Corixa                   CD20                       Non-Hodgkin's lymphoma
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###### 

FDA-approved checkpoint inhibitors.

  Name of Drug    Company                 Target   Indications
  --------------- ----------------------- -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ipilimumab      Bristol-Myers Squibb    CTLA-4   Unresectable or metastatic melanoma
  Tremelimumab    AstraZeneca             CTLA-4   Unresectable malignant mesotheliomaMetastatic melanomaNon-small-cell lung cancer
  Nivolumab       Bristol-Myers           PD-1     Unresectable or metastatic melanomaMetastatic non-small-cell lung cancerAdvanced renal cell carcinomaRecurrent or metastatic head and neck squamous cell carcinomaLocally advanced or metastatic urothelial carcinomaHepatocarcinoma
  Pembrolizumab   Merck                   PD-1     Unresectable or metastatic melanomaMetastatic non-squamous non-small-cell lung cancerRecurrent or metastatic head and neck squamous cell carcinomaRefractory Hodgkin lymphomaLocally advanced or metastatic urothelial carcinoma
  Atezolizumab    Roche                   PD-L1    Advanced or metastatic urothelial carcinomaMetastatic non-small-cell lung cancer
  Avelumab        Merck Pfizer            PD-L1    Locally advanced or metastatic urothelial carcinoma
  Durvalumab      MedImmune/AstraZeneca   PD-L1    Urothelial carcinomaNon-small-cell lung cancer
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###### 

Clinical trials of therapies targeting the MAPK pathway and immunotherapy in patients with melanoma.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  National Clinical Trial (NCT) Number   Title                                                                                                                Status                                                                    Conditions             Interventions                     Phase       Start Date
  -------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ---------------------- --------------------------------- ----------- -------------------
  NCT\                                   Ph I Ipilimumab Vemurafenib Combo in Patients with v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)             Terminated\                                                               •Melanoma              •Drug: Ipilimumab (BMS-734016)\   Phase 1     November 2011
  01400451                                                                                                                                                    (unexpected grade 2/3 hepatotoxicity)                                                            •Drug: Vemurafenib                            

  NCT\                                   Phase II Safety Study of\                                                                                            Completed\                                                                •Melanoma              •Drug: Ipilimumab\                Phase 2     13 September 2012
  01673854                               Vemurafenib Followed by\                                                                                             (no severe hepatotoxicity, but reported a grade 3/4 skin adverse event)                          •Biological: Vemurafenib                      
                                         Ipilimumab in Subjects with\                                                                                                                                                                                                                                        
                                         V600 BRAF Mutated Advanced\                                                                                                                                                                                                                                         
                                         Melanoma                                                                                                                                                                                                                                                            

  NCT\                                   Neoadjuvant Combination\                                                                                             Recruiting                                                                •Clinical stage\       •Drug: Atezolizumab\              Phase 2     22 June 2018
  03554083                               Targeted and Immunotherapy\                                                                                                                                                                    iii cutaneous\         •Drug: Cobimetinib\                           
                                         for Patients with High-Risk\                                                                                                                                                                   melanoma ajcc v8\      •Drug: Vemurafenib                            
                                         Stage III Melanoma                                                                                                                                                                             •Pathologic Stage\                                                   
                                                                                                                                                                                                                                        III Cutaneous\                                                       
                                                                                                                                                                                                                                        Melanoma AJCC v8\                                                    
                                                                                                                                                                                                                                        •Pathologic Stage\                                                   
                                                                                                                                                                                                                                        IIIA Cutaneous\                                                      
                                                                                                                                                                                                                                        Melanoma AJCC v8\                                                    
                                                                                                                                                                                                                                        •Pathologic Stage\                                                   
                                                                                                                                                                                                                                        IIIB Cutaneous\                                                      
                                                                                                                                                                                                                                        Melanoma AJCC v8\                                                    
                                                                                                                                                                                                                                        •Pathologic Stage\                                                   
                                                                                                                                                                                                                                        IIIC Cutaneous\                                                      
                                                                                                                                                                                                                                        Melanoma AJCC v8\                                                    
                                                                                                                                                                                                                                        •Pathologic Stage\                                                   
                                                                                                                                                                                                                                        IIID Cutaneous\                                                      
                                                                                                                                                                                                                                        Melanoma AJCC v8                                                     

  NCT\                                   Immunotherapy with Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy with Encorafenib and Binimetinib   Recruiting                                                                •Unresectable Stage\   •Drug: Nivolumab + Ipilimumab\    Phase 2     30 October 2018
  03235245                                                                                                                                                                                                                              III Melanoma\          •Drug: Encorafenib+ Binimetinib               
                                                                                                                                                                                                                                        •Stage IV Melanoma                                                   

  NCT\                                   A Study of the Anti-PD1 Antibody PDR001, in Combination with Dabrafenib\                                             Recruiting                                                                •Melanoma              •Biological:\                     Phase 3     17 February 2017
  02967692                               and Trametinib in Advanced\                                                                                                                                                                                           Spartalizumab (PDR001)\                       
                                         Melanoma                                                                                                                                                                                                              •Other: Placebo\                              
                                                                                                                                                                                                                                                               •Drug: Dabrafenib\                            
                                                                                                                                                                                                                                                               •Drug: Trametinib                             

  NCT\                                   Encorafenib + Binimetinib +\                                                                                         Recruiting                                                                •Malignant\            •Drug: Encorafenib\               •Phase 1\   24 April 2018
  02902042                               Pembrolizumab in Patients\                                                                                                                                                                     Melanoma               •Drug: Binimetinib\               •Phase 2    
                                         with Unresectable or Metastatic\                                                                                                                                                                                      •Drug: Pembrolizumab\                         
                                         BRAF V600 Mutant Melanoma                                                                                                                                                                                             •Drug: Pembrolizumabalone                     

  NCT\                                   Neoadjuvant Dabrafenib,\                                                                                             Recruiting                                                                •Melanoma              •Melanoma\                        Phase 2     8 November 2017
  02858921                               Trametinib and/or\                                                                                                                                                                                                    •Drug: Dabrafenib\                            
                                         Pembrolizumab in BRAF Mutant\                                                                                                                                                                                         •Drug: Trametinib\                            
                                         Resectable Stage III Melanoma                                                                                                                                                                                         •Drug: Pembrolizumab                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Clinical trials of therapies targeting the MAPK pathway and immunotherapies in patients with NSCLC.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  National Clinical Trial (NCT) Number   Title                              Status       Conditions                                     Interventions              Phase       Start Date
  -------------------------------------- ---------------------------------- ------------ ---------------------------------------------- -------------------------- ----------- -------------------
  NCT\                                   Study of Binimetinib\              Recruiting   •Non-Small-Cell\                               •Drug: Binimetinib\        •Phase 1    20 September 2019
  03991819                               in Combination with\                            Carcinoma                                      •Drug:\                                
                                         Pembrolizumab in Advanced\                                                                     Pembrolizumab                          
                                         Non-Small-Cell Lung Cancer                                                                                                            

  NCT\                                   Atezolizumab and Cobimetinib\      Recruiting   •Recurrent Lung\                               •Drug: Atezolizumab\       Phase 2     20 July 2018
  03600701                               in Treating Patients with\                      Non-Small-Cell\                                •Drug: Cobimetinib                     
                                         Metastatic, Recurrent, or\                      Carcinoma\                                                                            
                                         Refractory Non-Small-Cell Lung\                 •Refractory Lung\                                                                     
                                         Cancer                                          Non-Small-Cell\                                                                       
                                                                                         Carcinoma\                                                                            
                                                                                         •Stage IV Lung Non-\                                                                  
                                                                                         Small-Cell Cancer AJCC v7                                                             

  NCT\                                   Durvalumab, Tremelimumab,\         Recruiting   •Recurrent Lung\                               •Biological:\              •Phase 1\   1 April 2019
  03581487                               and Selumetinib in Treating\                    Non-Small-Cell Carcinoma\                      Durvalumab\                •Phase 2    
                                         Participants with Recurrent or\                 •Stage IV Lung\                                •Drug: Selumetinib\                    
                                         Stage IV Non-Small-Cell Lung\                   Cancer AJCC v8\                                •Biological:Tremelimumab               
                                         Cancer                                          •Stage IVA Lung\                                                                      
                                                                                         Cancer AJCC v8\                                                                       
                                                                                         •Stage IVB Lung\                                                                      
                                                                                         Cancer AJCC v8                                                                        

  NCT\                                   Pembrolizumab and Trametinib\      Recruiting   •KRAS Gene Mutation\                           •Biological:\              Phase 1     26 June 2018
  03299088                               in Treating Patients with Stage\                •Metastatic Non-\                              Pembrolizumab\                         
                                         IV Non-Small-Cell Lung Cancer\                  Squamous Non-\                                 •Drug: Trametinib                      
                                         and KRAS Gene Mutations                         Small Cell Lung Carcinoma\                                                            
                                                                                         •Recurrent Non-\                                                                      
                                                                                         Squamous Non-\                                                                        
                                                                                         Small Cell Lung\                                                                      
                                                                                         Carcinoma\                                                                            
                                                                                         •Stage IV Non-Small-Cell Lung Cancer AJCC v7                                          

  NCT\                                   Trametinib and Pembrolizumab\      Recruiting   •Metastatic Lung\                              •Biological:\              •Phase 1\   3 February 2018
  03225664                               in Treating Patients with\                      Non-Small-Cell Carcinoma\                      Pembrolizumab\             •Phase 2    
                                         Recurrent Non-Small-Cell Lung\                  •Recurrent Lung\                               •Other:\                               
                                         Cancer That Is Metastatic,\                     Non-Small-Cell Carcinoma\                      Pharmacokinetic\                       
                                         Unresectable, or Locally\                       •Stage III Lung\                               Study\                                 
                                         Advanced                                        Cancer AJCC v8\                                •Drug: Trametinib                      
                                                                                         •Stage IIIA Lung\                                                                     
                                                                                         Cancer AJCC v8\                                                                       
                                                                                         •Stage IIIB Lung\                                                                     
                                                                                         Cancer AJCC v8\                                                                       
                                                                                         •Stage IIIC Lung\                                                                     
                                                                                         Cancer AJCC v8\                                                                       
                                                                                         •Stage IV Lung\                                                                       
                                                                                         Cancer AJCC v8\                                                                       
                                                                                         •Stage IVA Lung\                                                                      
                                                                                         Cancer AJCC v8\                                                                       
                                                                                         •Stage IVB Lung\                                                                      
                                                                                         Cancer AJCC v8\                                                                       
                                                                                         •Unresectable Lung\                                                                   
                                                                                         Non-Small-Cell Carcinoma                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Clinical trials of therapies targeting the MAPK pathway in patients with colorectal cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  National Clinical Trial (NCT) Number   Title                                                                                               Status                   Conditions                                   Interventions                                      Phase      Start Date
  -------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------ -------------------------------------------- -------------------------------------------------- ---------- ----------------
  NCT\                                   A Phase I Study of Oral LGX818 in Adult Patients with Advanced or Metastatic BRAF Mutant Melanoma   Active, not recruiting   •Melanoma and Metastatic Colorectal Cancer   •Drug: LGX818                                      •Phase 1   September 2011
  01436656                                                                                                                                                                                                                                                                       

  NCT\                                   A Study of ARRY-438162 (MEK162) in Patients with Advanced Cancer                                    Completed                •Advanced Solid Tumors\                      •Drug: ARRY-438162 (MEK162), MEK inhibitor; oral   Phase 1    August 2009
  00959127                                                                                                                                                            •Advanced or Metastatic Biliary Cancer\                                                                    
                                                                                                                                                                      •Metastatic Colorectal Cancer                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Clinical trials investigating therapies targeting the MAPK pathway and immunotherapies in patients with colorectal cancer.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  National Clinical Trial (NCT) Number   Title                                                                              Status          Conditions               Interventions            Phase       Start Date
  -------------------------------------- ---------------------------------------------------------------------------------- --------------- ------------------------ ------------------------ ----------- ------------------
  NCT\                                   Encorafenib, Binimetinib,\                                                         Not yet\        •Metastatic Colon\       •Drug: Binimetinib\      •Phase 1\   1 December 2019
  04044430                               and Nivolumab in Treating\                                                         recruiting      Adenocarcinoma\          •Drug: Encorafenib\      •Phase 2    
                                         Patients with Microsatellite\                                                                      •Metastatic\             •Biological:\                        
                                         Stable BRAFV600E Metastatic\                                                                       Colorectal\              Nivolumab\                           
                                         Colorectal Cancer                                                                                  Adenocarcinoma\          •Other:\                             
                                                                                                                                            •Metastatic\             Questionnaire\                       
                                                                                                                                            Microsatellite\          Administration                       
                                                                                                                                            Stable Colorectal\                                            
                                                                                                                                            Carcinoma\                                                    
                                                                                                                                            •Metastatic Rectal\                                           
                                                                                                                                            Adenocarcinoma\                                               
                                                                                                                                            •Stage III Colon\                                             
                                                                                                                                            Cancer\                                                       
                                                                                                                                            •Stage III Colorectal\                                        
                                                                                                                                            Cancer\                                                       
                                                                                                                                            •Stage III Rectal\                                            
                                                                                                                                            Cancer\                                                       
                                                                                                                                            •Stage IIIA Colon\                                            
                                                                                                                                            Cancer\                                                       
                                                                                                                                            •Stage IIIA\                                                  
                                                                                                                                            Colorectal Cancer\                                            
                                                                                                                                            •Stage IIIA Rectal\                                           
                                                                                                                                            Cancer\                                                       
                                                                                                                                            •and 18 more                                                  

  NCT 03428126                           Study of Durvalumab\                                                               Enrolling by\   •Malignant\              •Drug: Durvalumab\       Phase 2     21 March 2018
                                         (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer       invitation      Neoplasms of\            •Drug: Trametinib                    
                                                                                                                                            Digestive Organs\                                             
                                                                                                                                            •Colorectal Cancer\                                           
                                                                                                                                            •Colon Cancer                                                 

  NCT 03374254                           Safety and Efficacy of\                                                            Recruiting      •Metastatic\             •Biological:\            Phase 1     16 February 2018
                                         Pembrolizumab (MK-3475)\                                                                           Colorectal Cancer        Pembrolizumab\                       
                                         Plus Binimetinib Alone\                                                                                                     •Drug: Binimetinib\                  
                                         or Pembrolizumab Plus\                                                                                                      •Drug: Oxaliplatin\                  
                                         Chemotherapy with or without Binimetinib in Metastatic Colorectal Cancer (mCRC)\                                            •Drug: Leucovorin\                   
                                         Participants (MK-3475-651)                                                                                                  •Drug: 5-Fluorouracil\               
                                                                                                                                                                     \[5-FU\]\                            
                                                                                                                                                                     •Drug: Irinotecan                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Clinical trials of therapies targeting the MAPK pathway and immunotherapies in patients with pancreatic cancer.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  National Clinical Trial (NCT) Number   Title                                                                                                                                                          Status       Conditions                   Interventions           Phase       Start Date
  -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ---------------------------- ----------------------- ----------- ----------------
  NCT\                                   A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus Pancreatic Cancer)   Recruiting   •Pancreatic Adenocarcinoma   •Drug: NabPaclitaxel\   •Phase 1\   5 July 2017
  03193190                                                                                                                                                                                                                                        •Drug: Gemcitabine\     •Phase 2    
                                                                                                                                                                                                                                                  •Drug: Oxaliplatin\                 
                                                                                                                                                                                                                                                  •Drug: Leucovorin\                  
                                                                                                                                                                                                                                                  •Drug: Fluorouracil\                
                                                                                                                                                                                                                                                  •Drug: Atezolizumab\                
                                                                                                                                                                                                                                                  •Drug: Cobimetinib\                 
                                                                                                                                                                                                                                                  •Drug: PEGPH20\                     
                                                                                                                                                                                                                                                  •Drug: BL-8040\                     
                                                                                                                                                                                                                                                  •Drug: Selicrelumab\                
                                                                                                                                                                                                                                                  •and 3 more                         

  NCT\                                   A Study of Avelumab, Binimetinib and Talazoparib in Patients with Locally Advanced or Metastatic RAS-mutant Solid Tumors                                       Recruiting   •Pancreatic Cancer           •Drug: Avelumab\        Phase 2     15 August 2018
  03637491                                                                                                                                                                                                                                        •Drug: Binimetinib\                 
                                                                                                                                                                                                                                                  •Drug: Talazoparib                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Clinical trials investigating combined MAPK pathway-targeted therapy and immunotherapy in patients with thyroid cancer.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  National Clinical Trial (NCT) Number   Title                                                                                                                                               Status               Conditions                                                   Interventions            Phase     Start Date
  -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------------------------ ------------------------ --------- ----------------
  NCT\                                   Encorafenib and Binimetinib with or without Nivolumab in Treating Patients with Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer   Not yet recruiting   •BRAF NP_004324.2:p.V600M •BRAF V600E Mutation Present\      •Drug: Binimetinib\      Phase 2   30 August 2019
  04061980                                                                                                                                                                                                        •Metastatic Thyroid Gland Carcinoma\                         •Drug: Encorafenib\                
                                                                                                                                                                                                                  •Refractory Thyroid Gland Carcinoma\                         •Biological: Nivolumab             
                                                                                                                                                                                                                  •Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8\                                       
                                                                                                                                                                                                                  •Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8\                                      
                                                                                                                                                                                                                  •Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8                                       

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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